Detail akcie Lenz Ther Rg online

Business Summary: LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lenz Therapeutics Inc revenues increased from $0K to $17.5M. Net loss increased 25% to $46.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $16.2M to $44.3M (expense), Stock-based Compensation in SGA increase from $3.2M to $7.2M (expense).